Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DEBORAH ANN YORK

Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Psychiatric/Mental Health

NPI
1952823403
CMS profile
10780730
Location
DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$22,928.67

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $11,874.86 30
Alkermes, Inc. $10,366.66 32
Vanda Pharmaceuticals Inc. $592.98 7
Boehringer Ingelheim Pharmaceuticals, Inc. $94.17 1

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DEBORAH ANN YORK

NPI 1952823403 · CMS profile ID 10780730

Physician Assistants & Advanced Practice Nursing Providers / Nurse Practitioner / Psychiatric/Mental Health

DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952823403?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DEBORAH ANN YORK, NPI 1952823403, CMS profile ID 10780730. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952823403?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DEBORAH ANN YORK, NPI 1952823403, CMS profile ID 10780730. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952823403?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DEBORAH ANN YORK, NPI 1952823403, CMS profile ID 10780730, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1952823403?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $22,928.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–70 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $751.5002/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309785 CMS
ABBVIE INC. $2,200.0002/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309781 CMS
Alkermes, Inc. $8.5602/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946309 CMS
Alkermes, Inc. $47.9601/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946299 CMS
Alkermes, Inc. $90.0001/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946301 CMS
Alkermes, Inc. $128.5201/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946303 CMS
Alkermes, Inc. $623.7301/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946305 CMS
Alkermes, Inc. $28.7501/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946307 CMS
Alkermes, Inc. $30.0001/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946295 CMS
Alkermes, Inc. $22.5001/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946297 CMS
ABBVIE INC. $22.5201/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309757 CMS
ABBVIE INC. $45.7001/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309761 CMS
ABBVIE INC. $47.2101/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309765 CMS
ABBVIE INC. $300.8001/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309769 CMS
ABBVIE INC. $315.8101/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309773 CMS
ABBVIE INC. $764.9601/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309777 CMS
ABBVIE INC. $111.0701/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309754 CMS
Alkermes, Inc. $119.4701/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946293 CMS
ABBVIE INC. $21.0701/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1010309751 CMS
Alkermes, Inc. $1,400.0001/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022946291 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $16,696.38 48
PY2022 $38,842.79 81
PY2023 $22,928.67 70
PY2024 $69,046.58 133
PY2025 $10,489.35 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $178,060.08 45
PY2024 Principal investigator $117,595.97 18
PY2023 Principal investigator $257,009.96 5
PY2022 Principal investigator $48,555.11 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $1,430.88 12/24/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620592
Principal investigator 1 Alkermes, Inc. $2,098.80 12/24/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624528
Principal investigator 1 Alkermes, Inc. $498.00 12/19/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208619903
Principal investigator 1 Vanda Pharmaceuticals Inc. $8,068.20 12/19/2025 Non-covered Recipient Entity
MOUNTAIN MIND
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232947250
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,160.84 12/18/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232947234
Principal investigator 1 Alkermes, Inc. $1,347.50 12/08/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614651
Principal investigator 1 Alkermes, Inc. $1,430.88 11/21/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621620
Principal investigator 1 Alkermes, Inc. $2,098.80 11/21/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622275
Principal investigator 1 Alkermes, Inc. $498.00 10/27/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614144
Principal investigator 1 Alkermes, Inc. $1,500.00 10/27/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614809
Principal investigator 1 Alkermes, Inc. $2,927.76 10/22/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613265
Principal investigator 1 Alkermes, Inc. $1,430.88 10/22/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616523
Principal investigator 1 Alkermes, Inc. $2,987.16 10/22/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617135
Principal investigator 1 Alkermes, Inc. $1,477.08 10/22/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208619905
Principal investigator 1 Alkermes, Inc. $2,300.00 10/10/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622703
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,392.76 10/07/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232946489
Principal investigator 1 Alkermes, Inc. $10,542.00 10/02/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208612823
Principal investigator 1 Alkermes, Inc. $2,987.16 09/25/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615469
Principal investigator 1 Alkermes, Inc. $2,300.00 09/17/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622163
Principal investigator 1 Alkermes, Inc. $7,500.00 09/17/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624410
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,303.36 09/12/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232946355
Principal investigator 1 Vanda Pharmaceuticals Inc. $615.25 09/12/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232946359
Principal investigator 1 Alkermes, Inc. $2,987.16 09/10/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624408
Principal investigator 1 Vanda Pharmaceuticals Inc. $334.99 08/01/2025 Non-covered Recipient Entity
MOUNTAIN MIND
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946003
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,427.48 07/25/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945981
Principal investigator 1 Vanda Pharmaceuticals Inc. $11,200.00 07/25/2025 Non-covered Recipient Entity
MOUNTAIN MIND
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232945985
Principal investigator 1 Vanda Pharmaceuticals Inc. $29.83 07/08/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945757
Principal investigator 1 Vanda Pharmaceuticals Inc. $500.65 07/08/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945761
Principal investigator 1 Vanda Pharmaceuticals Inc. $8,279.04 07/08/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945765
Principal investigator 1 Alkermes, Inc. $10,542.00 06/23/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208612787
Principal investigator 1 Alkermes, Inc. $7,500.00 06/23/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613655
Principal investigator 1 Alkermes, Inc. $205.00 06/13/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613858
Principal investigator 1 Alkermes, Inc. $1,347.50 06/13/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623598
Principal investigator 1 Alkermes, Inc. $70.00 06/10/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613217
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,754.28 05/31/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945505
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,280.40 04/25/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945291
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,844.00 04/08/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945081
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,936.04 04/08/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232945085
Principal investigator 1 Vanda Pharmaceuticals Inc. $817.26 03/18/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232944989
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,394.08 02/28/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232944927
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,076.92 02/14/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232944775
Principal investigator 1 Vanda Pharmaceuticals Inc. $567.80 01/06/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232944471
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,280.40 01/06/2025 Non-covered Recipient Entity
DEBORAH A YORK
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232944475
Principal investigator 1 Alkermes, Inc. $17,156.90 01/01/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208627015
Principal investigator 1 Alkermes, Inc. $19,633.04 01/01/2025 Non-covered Recipient Entity
MOUNTAIN MIND, LLC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208627052